To view this email as a web page, click here

Today's Rundown

Featured Story

3 very different biotechs all file for the same IPO goal: A big raise on Nasdaq

A stem cell biotech, a liver disease specialist and a gene therapy company have all got in the conga line for the biotech IPO boom.

read more

Top Stories

Rejuvenate Bio banks $10M to advance gene therapy for aging in humans and dogs

Rejuvenate Bio raised more than $10 million in its series A round to propel its gene therapy toward the market for the treatment of heart disease in dogs and toward the clinic for the treatment of aging-related conditions in humans, including heart failure, kidney failure, Type 2 diabetes and obesity.

read more

Adagio raises a monster $336M round for bespoke COVID-19 drug battle

Adagio Therapeutics has nabbed a massive $336 million series C from a who’s who of investors as it more than triples its previous funding drive last year.

read more

Sponsored: Why Integrated Partners are Critical to Cell and Gene Therapy Success

Working with the right integrated partner can help ease increasingly common problems with scale, access to high-demand raw material, viral vector production and quality requirements. 

read more

Tonix hopes for COVID-19 drug tonic as it pens OyaGen antiviral pact

Tonix Pharmaceuticals is opening an early-stage antiviral asset deal with OyaGen as the pair targets COVID-19.

read more

Lyndra's ultralong-acting pill shows promise in schizophrenia phase 2, teeing up pivotal trial

In a phase 2 study, patients taking Lyndra Therapeutics’ once-weekly schizophrenia pill, LYN-005, quickly reached therapeutic levels of the drug, according to data presented virtually Sunday at the Congress of the Schizophrenia International Research Society. The study pitted Lyndra’s treatment, an ultralong-acting version of the antipsychotic risperidone, against immediate-release risperidone in 34 patients diagnosed with schizophrenia or schizoaffective disorder.

read more

Epizyme's EZH2 blocker boosts immuno-oncology response in prostate cancer models

Cedars-Sinai Cancer researchers showed in preclinical models of prostate cancer that blocking the enzyme EZH2 reduces resistance to immune-boosting checkpoint inhibitors—and they did it with the help of Epizyme, which won FDA approval for the first EZH2 blocker last year. They're now planning a clinical trial.

read more

The top 10 ad spenders in Big Pharma for 2020

Even as other industries slashed ad budgets, pharma advertisers continued to spend on TV and digital especially—reaching a total of $6.6 billion in 2020.

read more

Zymeworks' first CMO moves on as lead cancer candidate heads for commercialization

Zymeworks CMO Diana Hausman, M.D., will pass the torch to Neil Josephson, M.D., who currently oversees the Canadian biotechnology company’s global clinical studies.

read more

Could this common heart drug defeat obesity by preventing inflammation?

Spanish researchers discovered that digoxin, a drug used to treat heart failure and rhythm disorders, could be an effective strategy for treating obesity. The drug tamped down an inflammatory molecule called interleukin 17A (IL-17A), in mouse models of obesity, promoting weight loss, they reported.

read more

Resources

Content Hub: Process Intensification Resource Center

A one-stop hub for Cytiva resources to support process intesification

Whitepaper: COVID-19 Survey report: The Lasting Impact on Outsourcing Decisions

How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond?

Content Hub: Emerging Biotech Resource Center

A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule

Whitepaper: Top 5 Benefits of a Cloud ELN

Discover the benefits of a cloud-native ELN that delivers better performance, security, connectivity, total cost of ownership PLUS sub-second search results through even the largest data volumes.

Special Report: The Marketer’s Guide to Taking the Vaccine Viral

Access this guide for the latest insights into how marketers can use data, technology, and personalized messaging to build vaccine confidence and drive successful immunization efforts.

Content Hub: How to improve the virtual work you do every day

We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met.

Report: New research indicates an accelerated shift to decentralized clinical trials

New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.

Whitepaper: Roche to pick up GenMark Diagnostics in $1.8B infectious disease testing deal

Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously.

Content Hub: Remarque Systems Resource Hub

Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. 

Whitepaper: New Data: A Better Way to Run CHO Cell Culture Experiments

Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly.

Whitepaper: Overcoming the hurdles of Real-World Data Access through a federated global network

Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights.

Report: New research indicates an accelerated shift to decentralized clinical trials

New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19.

Executive Summary: Manufacturing Strategies to Effectively Industrialize Autologous Cell Therapies

Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

eBrief: Drug Product Process Development: Ensuring a Consistent, High-quality Biologic

Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase.

Whitepaper: Achieving a Successful Drug Product Technology Transfer

Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent.

Whitepaper: The Art of Recognizing Clinical Supply Risk Factors

In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management.

eBook: Expecting the Unexpected: Strategies for Efficient Clinical Supply Management and Forecasting

Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study.

Events